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Zusammenfassung 
Der Fibroblast Growth Factor (FGF23) ist ein Hormon, das im Knochen gebildet wird 
und die Phosphatausscheidung steigert. Es ist ein wichtiger Regulator des Vitamin D-
Stoffwechsels und des Phosphathaushalts. Es wird im Knochen gebildet und wirkt 
hauptsächlich in der Niere. FGF23 hemmt das Enzym 25-Dihdroxyvitamin D 1α-
hydroxylase und reduziert somit die blidung des biologisch aktiven Vitamin d-Hormones 
und stimuliert dessen Abbau durch die 25-Dihydroxyvitamin D 24-hydroxylase. Es 
blockiert die renale Phosphatreabsorption im proximalen Nierentubulus und erniedrigt 
damit die Serumphosphatkonzentration sowie die Konzentration von aktivem Vitamin D. 
Die Glykogensynthasekinase (GSK3) ist eine ubiquitär exprimierte Serin-
/Threoninkinase. Sie ist in eine Vielzahl von zellulären Prozessen eingebunden, z.B. in 
den Glykogenstoffwechsel, die Transkription und Translation, Proliferation und 
Überleben der Zellen, die Regulation des Zell-Zyklus, die reorganisation des 
Zytoskeletts und die Apoptose. Die GSK3 ist ein Signalmolekül des PI3Kinase- 
Stoffwechsels. Sie wird durch den Insulin-abhängigen PKB/Akt-Signalweg 
phosphoryliert und dadurch blockiert. Transgene Mäuse, welche PKB-insensitives 
GSK3α/β (gsk-3kI) exprimieren, zeigen erhöhte Aktivität des sympathischen 
Nervensystems und Phosphaturie sowie erniedrigte Knochendichte. Es ist bereits 
bekannt, dass der Sympathikus die FGF23-Sekretion fördert. Im ersten Teil der Studie 
wurde die Rolle der GSK-kontrollierten Sympathikusaktivität für die Bildung von FGF23 
und die Regulation des Phosphatstoffwechsels untersucht. Serum FGF23, 
Adrenalinausscheidung im urin, Vanillinmandelsäure, Phosphat und 
Kalziumausscheidung waren signifikant höher in gsk-3kI Mäusen im Vergleich zu gsk-
3WT Mäusen. Die Serum-FGF23 und 1,25(OH)2D3-Konzentrationen waren niedriger in 
gsk-3KI Mäusen als in gsk-3WT Mäusen. Die Mäuse wurden eine Woche mit einem β-
Blocker (propranolol) im Trinkwasser behandelt. Die Propranololbehandlung erniedrigte 
den Serum-FGF23, den renalen Phosphat-und Kalziumverlust und erhöhte die Serum 
Phosphatkonzentration in gsk-3KI Mäusen. Damit wurde gezeigt, dass die PI3Kinase-
insensitive GSK3 an der Regulation der FGF23-Bildung, des Vitamin D Metabolismus 
und somit auch des Mineralstoffwechsels durch das sympathische Nervensystem 
mitwirkt. Im zweiten Teil der Studie Rolle der Reorganisation des Aktin-Zytoskeletts für 
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die Kontrolle der FGF23 Produktion untersucht. Es ist bekannt, dass 1,25(OH)2D3 und 
NF-κB die FGF23-Bildung steigern. Um die Rolle der 1,25(OH)2D3-induzierten 
Aktinpolymerisation für die Fgf23 Transkription in UMR 106 Osteoblasten ähnlichen 
Zellen zu untersuchen, wurde die Dynamik der Aktinpolymerisation durch Western Blot 
und konfokale Mikroskopie verfolgt und die Fgf23-Transkription mit quantitativer RT-
PCR gemessen. Es konnte gezeigt werden, dass die Induktion der FGF23-Produktion 
durch 1,25(OH)2D3 in Aktinpolymerisation resultiert. Dieser Effekt wurde durch die 
pharmakologische Hemmung des NF-kB durch Wogonin blockiet. Cytochalasin B, eine 
Substanz, welche Aktinfilamente depolymerisiert, hat die 1,25(OH)2D3  induzierte Fgf23 
Transkription behindert. Dieses Resultat deuten auf eine entscheidende Rolle des 
Aktinzytoskeletts für die Fgf23-Transkription hin. Zur Identifikation der 
zugrundeliegenden Signaltransduktion wurden die Zellen mit dem Rac1-inhibitor NSC 
23766 und den PAK-inhibitor IPA3 behandelt. Beide Inhibitoren blockierten die 
1,25(OH)2D3 induzierte FGF23 Expression, so dass der Rac1/PAK-Signalweg an dem 
Effekt beteiligt ist. Die vorliegenden Ergebnisse liefern einen starken Beweis dafür, dass 
die Rac1 regulierte Aktinreorganisation einen wichtigen Beitrag für die 1,25(OH)2D3-
induzierte FGF23-Bildung liefert.  
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Summary 
Fibroblast growth factor (FGF) 23 is a bone derived phosphaturic hormone. It is a potent 
regulator of vitamin D metabolism and phosphate homeostasis. FGF23 is secreted from 
the bone and exerts its function on the kidney. Further, it inhibits 25-dihydroxyvitamin D 
1α-hydroxylase and reduces formation of active vitamin D and stimulates 25-
dihydroxyvitamin D 24-hydroxylase, which in turn favors degradation of vitamin D. 
FGF23 inhibits renal phosphate reabsorption in the proximal tubules, thereby lowering 
serum phosphate and active vitamin D. To exert its renal function, FGF23 requires 
klotho as a co-receptor. Both FGF23 and klotho deficiency, lead to vascular 
calcification, hyperphosphatemia, hypercalcemia, muscular atrophy and profound aging 
like phenotypes. Glycogen synthase kinase (GSK) 3 is a serine-threonine kinase, which 
is ubiquitously expressed and involved in a variety of cellular process including; 
glycogen metabolism, transcription, translation, proliferation, survival, cell cycle 
regulation, cytoskeleton reorganization and apoptosis. GSK3 is a downstream signaling 
molecule of phosphoinositide-3 kinase (PI3 kinase)/PKB/Akt pathway. Mice expressing 
PKB insensitive GSK3α/β (gsk-3ki) show enhanced sympathetic nervous activity and 
phosphaturia with low bone density. The sympathetic nervous system was shown to 
stimulate FGF23 release. In this thesis, I investigated the role of GSK3-controlled 
sympathetic activity in the production of FGF23 and phosphate metabolism. Serum 
FGF23, urinary epinephrine, Vanillylmandelic acid (VMA), phosphate and calcium 
excretion were significantly higher in gsk-3ki mice compared to gsk-3WT mice. Serum 
FGF23 and 1,25(OH)2D3 concentrations were lower in gsk3
KI mice than in gsk-3WT mice. 
Mice were treated with β-blocker (propranolol) for one week resulted in decreased 
serum FGF23 and renal phosphate and calcium loss and elevated serum phosphate 
concentration in gsk-3KI mice. Thus, these data suggest that PI3K insensitive GSK3 
participates in the regulation of FGF23 formation, vitamin D metabolism and, thereby 
mineral metabolism by sympathetic nervous system. 
Next, I explored the role of actin cytoskeleton reorganization in controlling FGF23 
production. Previous findings have suggested that 1,25(OH)2D3 and NF-κB stimulates 
FGF23 production. Therefore, the role of 1,25(OH)2D3-induced actin polymerization on 
Fgf23 expression in UMR 106 osteoblast-like cells was explored. Actin polymerization 
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dynamics was determined by Western blotting and confocal imaging and Fgf23 
transcript levels was measured by qRT-PCR. Western blotting and confocal imaging 
data showed 1,25(OH)2D3 induces actin polymerization in UMR 106 osteoblast-like 
cells. Thus induction of FGF23 production by 1,25(OH)2D3 resulted in actin 
polymerization, an effect blocked by the pharmacological inhibitor of NF-κB wogonin 
(100 µM). Cytochalasin B (100 nM) is a actin microfilament disrupting agent which 
abolished 1,25(OH)2D3-induced Fgf23 gene transcription, pointing a role of actin 
cytoskeleton in Fgf23 expression. Both Rac1 inhibitor NSC23766 (50 µM) and IPA3 (10 
µM) blocked 1,25(OH)2D3-induced Fgf23 expression, suggesting the mechanism 
involved in actin cytoskeleton- controlled Fgf23 expression in UMR 106 cells involves 
Rac1 small GTPase signaling. These results provide strong evidence that actin 
reorganization regulated by Rac1 signaling contributes to 1,25(OH)2D3-induced Fgf23 
gene transcription.   
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1. Introduction   
 
Fibroblast growth factors (FGF) are a large family of secreted proteins. There are 22 
members of this family which have been found in both human and mice (1). FGFs 
function by binding to FGF receptors (FGFR) and transduce signals by different 
pathways which are involved in the regulation of many cellular processes including 
differentiation, cell proliferation or migration (2). 
 
1.1 FGF23 
 
Fibroblast growth factor (FGF) 23, a member of the FGF19 subfamily of the fibroblast 
growth factor, has been proposed as a potent regulator of mineral ion homeostasis (3-
6). FGF23 is a ~ 32 kDa secreted protein of 251 amino acids, which has a hydrophobic 
signal sequence (~24 amino acids), a N-terminal FGF core homology domain (155 
amino acids), and a C-terminal domain (72 amino acids). Human cDNA encoding 
FGF23 (251 amino acids) highly resembles (~72% amino acid identity) to mouse 
FGF23. Human Fgf23 gene is localized on the chromosome 12p13 and is mainly 
expressed in osteocytes (7-10). The C-terminal domain is necessary for the interaction 
with the FGFR. The proteolytic cleavage site (176RXXR179) is found between N- and 
C-terminal domain (11) (Fig.1). The FGF23 protein is proteolytically cleaved and this 
processing occurs intracellularly, either before or during the secretion of FGF23 (12). 
Abnormalities of bone and mineral metabolism are associated with increased risk of 
mortality in chronic kidney diseases (CKD) including; hyperphosphatemia (13, 14), 
hypo- and hypercalcemia (15), hypo and hyperparathyroidism (16) and 
hyperphosphatasemia (17). Inorganic phosphate is an important factor in intracellular 
signaling, DNA synthesis and metabolism. In spite of its biological significance, 
regulation of phosphate homeostasis is not clear. A mutation in phosphate regulating 
endopeptidase homolog, X-linked (PHEX) causes X-linked hypophosphatemia (XLH) 
(18) and autosomal dominant hypophosphatemic rickets (ADHR) is caused by mutation 
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in FGF23 (19, 20), have been considered important regulators of phosphate 
homeostasis.    
 
 
 
Fig. 1: Structure of FGF23. FGF23 is a secreted protein consists of 251 amino acids. C-terminal FGF23 
is the inactive form which is proteolytically cleaved between Arg
179 
and Ser
180
 from intact FGF23 which is 
the biologically active form, adapted from Saito T et al, Int J Pediatr Endocrinol. 2009 (21). 
 
1.2 Discovery of FGF23 
 
Hypophosphatemic diseases in the many parts of the world have been caused by 
malnutrition and vitamin D deficiency. The most common cause of vitamin D resistant 
rickets is X-linked hypophosphatemic rickets (XLH) and other diseases, include 
autosomal dominant hypophosphatemic rickets (ADHR) and tumor-induced 
osteomalacia (TIO) with similar phenotypes (22). The murine analogue of human 
(FGF23) was cloned for the first time in 2000 in mice (7). It has been shown that ADHR 
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is caused by mutation on chromosome 12p13.3 and the mutated gene encodes the 251 
amino acid human FGF23 protein (6, 19, 20). Analysis of the structure revealed that 
mutations occurred in ADHR were situated within a subtilisin-like proprotein convertase 
(SPC) cleavage site in FGF23 that renders the protein resistant to degradation, resulting 
in increased serum levels of active FGF23 and hypophosphatemia due to increasing 
urinary Pi loss in ADHR patients (6, 12, 23). Tumor-induced osteomalacia (TIO) was 
thought as a vitamin D resistant osteomalacia causing hypophosphatemia which was 
cured by the removal of tumor (22, 24). Transplantation of these tumors into wild type 
mice caused hypophosphatemia with a production of a phosphaturic factor that can 
suppress 1,25(OH)2D3 and decrease renal Pi reabsorption (25, 26). Further, a mutation 
in FGF23 is responsible for ADHR, at the same time the FGF23 protein was shown to 
be produced in TIO (20, 27, 28).  
 
 
1.3 Source of FGF23 
 
FGF23 is expressed primarily in bone, thymus, brain, lymph nodes and to a lesser 
extent in heart, skeletal muscle, spleen, thyroid/parathyroid gland, lung and testis (4, 7, 
8, 10, 28). In bone, FGF23 is mainly localized to osteocytes and osteoblasts (8, 10). In 
the brain, expression of FGF23 was found in the ventrolateral thalamic nuclei (7).  
 
1.4 Phenotypes of Fgf23 mice 
 
1.4.1 Fgf23 deficient mice  
 
To interpret the physiological roles of FGF23 in mice, Fgf23 knockout mice were 
generated by Shimada et al., in 2004 (3). FGF23 is produced from bone (29, 30) and its 
biological function depends on the interaction with a cofactor protein called Klotho (31-
33). Fgf23 knockout mice suffer from severe hyperphosphatemia and elevated levels of 
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1,25(OH)2D3 due to enhanced renal 1α-hydroxylase expression and abnormalities in 
skeletal muscle (4). Genetic deletion of Fgf23 results in aging like phenotypes similar to 
human premature aging, including growth retardation, infertility, atherosclerosis, 
massive soft tissue calcifications, atrophy of multiple organ systems together with 
hypoglycemia and increased peripheral insulin sensitivity, disorder of phosphate and 
vitamin D metabolism, pulmonary emphysema, osteoporosis, and a severely shortened 
lifespan (3, 4, 34).  
 
 
1.4.2 Fgf23 transgenic mice 
 
A previous study suggested that recombinant FGF23 was able to enhance urinary 
phosphate excretion and lower serum 1,25(OH)2D3 when given in vivo (3). 
Overexpressing human wild-type FGF23 in transgenic mice exhibited  
hypophosphatemia and enhanced renal phosphate excretion which was accompanied 
by reduced expression of the sodium-dependent phosphate cotransporter types IIa 
(NaPi-2a) and IIc (NaPi-2c) in the kidney (35). Renal phosphate loss resulted in skeletal 
abnormalities and reduced bone mineral density (BMD) in these transgenic mice (35, 
36). Similarly, transgenic mice over expressing mutant form of FGF23 (human 
(R176Q)), which is resistant to degradation by furin-like proteases, displayed more 
pronounced hypophosphatemia and rickets/osteomalacia compared to animals 
expressing the wild-type FGF23 (37-39).  
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1.5 Function of FGF23 
 
1.5.1 FGF23 and Klotho 
 
FGF23 is produced by the bone and acts on kidney and transduces signals through 
FGF receptors (FGFR) (4, 10, 40, 41). There are four FGFRs and several subtypes 
formed as a result of alternative splicing. Although FGFRs differ in tissue expression, 
activity and ligand binding, all members of the receptor belong to tyrosine kinase family 
(42). However, binding affinity of FGF23 to its receptors (FGFRs) is poor (32). Following 
administration of recombinant FGF23 in mice, it was found that FGF23 binds to klotho, 
an aging counteracter, membrane-bound protein and induces the early growth response 
gene -1 (Egr-1) expression and ERK phosphorylation in the kidney, the parathyroid and 
pituitary gland (32). Klotho deficient mice and Fgf23 deficient mice both display high 
1,25(OH)2D3 levels, hyperphosphatemia, a shortened life span and severe aging 
phenotypes (3, 4, 43). Kurosu et al. have shown that Klotho complexed with FGFR1c, 
3c and 4, FGF23 bound tightly and transduce signal to the target organ (31). An in vivo 
study demonstrated that Klotho converted the FGFR1c to a functional FGF23 receptor 
and Klotho acts as a co-receptor for FGF23 signaling (32). The importance of the 
FGFR1 in FGF23 signaling has further been supported by in vivo studies of FGFR3/4 
null mice and conditional knock-out of FGFR1 mice (44). FGF23 signaling, requires 
FGFR1c and Klotho form a complex with FGF23 (Fig. 2), which is trimerized and 
stabilized by heparin sulphates as seen in other FGFR signaling complexes (45) 
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Fig. 2: Formation of heterotrimer complex of FGF23 with FGFR and klotho to transmit signal. To 
mediate renal effects, FGF23 bind to its receptor which requires Klotho as a co-receptor and form a 
complex, adapted from Saito T et al, Int J Pediatr Endocrinol. 2009 (21). 
 
1.5.2 Renal functions of FGF23 
 
Excessive FGF23 leads to hypophosphatemia, abnormal vitamin D metabolism, 
impaired growth and rickets/osteomalacia (35, 38, 46). Fgf23 deficient mice results in 
hyperphosphatemia, excess 1,25(OH)2D3 and calcification of soft tissues (3, 8). The 
kidney is the major target organ of FGF23 actions, deregulation of FGF23 can lead to 
various disorders. Renal functions of FGF23 are given below:  
 
1.5.3 Vitamin D metabolism 
 
FGF23 functions as counter regulatory hormone of vitamin D (47). Cyp27b1 and 
Cyp24a1 are key renal enzymes which are responsible for the synthesis of the bioactive 
form of vitamin D and degradation of the bioactive form of vitamin D respectively (21, 
40). FGF23 can influence circulating vitamin D levels through suppression of 25-
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hydroxyvitamin D 1-α-hydroxylase (Cyp27b1) and stimulation of 1,25-dihydroxyvitamin 
D 24-hydroxylase (Cyp24a1) in the proximal tubules which results in decreased serum 
concentration of 1,25(OH)2D3, the biologically-active form of vitamin D (28, 35, 38, 48-
50). FGF23 stimulates 1,25-dihydroxyvitamin D 24-hydroxylase Cyp24a1 expression 
(50) that leads to the reduction of serum 1,25(OH)2D3 levels are vitamin D receptor 
(VDR) dependent (51). Recombinant FGF23 injected into wild type mice reduces renal 
expression of Cyp27b1 dose-dependently and its effect on Cyp27b1 gene expression is 
ERK1/2 dependent (52). On the other hand, up regulation of Cyp27b1 mRNA 
expression is associated with higher FGF23 levels (53, 54). These studies suggest that 
the effect of FGF23 on the enzymes that are responsible for synthesis and degradation 
of 1,25(OH)2D3 depends on the circulatory FGF23 concentrations (3, 38, 50, 55). 
 
1.5.4 Phosphate reabsorption 
 
Cross-organ communication between kidneys, intestine and bones play a central role in 
phosphate homeostasis (56). It adjusts intestinal absorption of phosphate from the diet 
and renal reabsorption / excretion of phosphate that typically regulate phosphate 
balance. Phosphate reabsorption is taken place in the renal proximal tubule (Fig. 3) 
(40). The intestinal absorption and renal reabsorption of phosphate is mediated  by 
sodium-dependent phosphate transporter system that includes NaPi-2a (kidney), NaPi-
2b (intestine) and NaPi-2c (kidney) (57-61). It has been reported that FGF23 inhibits the 
expression of NaPi-2a and NaPi-2c which induces renal phosphate excretion (44, 50). 
Transgenic mice over expressing Fgf23 have severe hypophosphatemia due to the 
reduction of renal NaPi co transporters expression (36, 38). On the other hand, Fgf23 
knockout mice suffer from hyperphosphatemia and soft tissue calcification with 
enhanced renal NaPi-2a abundance (4, 62). Reduced renal NaPi-2a expression 
restores the biological effects of FGF23 in Fgf23 null mice significantly reversed 
hyperphosphatemia to hypophosphatemia and prevent calcification (63) 
. 
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Fig. 3: Schematic illustration for the functions of FGF23 in kidney and extra renal organs. (A) 
FGF23 activates FGFR/Klotho complex which lead to the inhibition of tubular phosphate reabsorption by 
inhibiting Npt2a. FGF23 inhibits Cyp27b1 in the proximal convoluted tubule (PCT), a key enzyme 
responsible for 1,25(OH)2D3 synthesis and stimulate Cyp24a1 which favor catabolism of 1,25(OH)2D3. 
Therefore, both phosphate and 1,25(OH)2D3 levels are decreased. (B) Extra renal targets of FGF23 are 
those tissue or organ which express FGFR and klotho i.e Bone, heart, brain, thymus, spleen and 
parathyroid gland (PT) which mediate possible effects of FGF23 , adapted from Martin A et al, Physiol 
Rev. 2012 (40). 
 
1.6 FGF23 and diseases 
 
1.6.1 Possible role of FGF23 in the premature aging 
 
Pathophysiology of aging is a complex biological process that involves multi-organ and 
multi-system pathologies (64-66). Klotho mutant mice display multiple aging-like 
features including shortened lifespan, infertility, skin atrophy, soft tissue calcification, 
atherosclerosis, muscles wasting, disorder of mineral ion metabolism and aberrant 
vitamin D metabolism (67, 68). A recent study suggests that aging like phenotypes in 
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klotho knockout mice are the consequence of abnormal mineral metabolism due to 
inability of Fgf23 gene function in these mice (69). Ablation of Fgf23 shares same 
phenotypes as found in the klotho null mice (70). Thus, common phenotypes of these 
mice are due to either absence (Fgf23 null mice) or lack of FGF23 activity (klotho 
mutant mice) (71).  
 
1.6.2 Hypervitaminosis-D and premature aging in Fgf23 mutant mice 
 
Both klotho and Fgf23 deficient mice show up-regulation of 25-hydroxyvitamin D 1-α-
hydroxylase (Cyp27b1) in the kidney and thereby increased serum levels of 
1,25(OH)2D3 (3, 4, 72), which are associated with aging like-features. The premature 
aging like-phenotypes in these mutants were rescued by feeding a vitamin-D deficient 
diet (73, 74) or genetically disrupting vitamin-D activities from Fgf23 mice (70, 73). By 
deleting 1-α hydroxylase gene from Fgf23 null mice, which is responsible for calcitriol 
synthesis, most of the phenotypes were ameliorated in Fgf23/1-α hydroxylase double 
knockout mice (70, 75). Thus, most of the aging like-features in Fgf23 and klotho null 
mice are due to abnormal mineral metabolism caused at least in part by 
hypervitaminosis-D (70, 76, 77). 
 
1.6.3 Hyperphosphatemia and aging 
 
Renal NaPi2a regulates plasma and urinary phosphate balance (60, 62). Renal 
abundance of NaPi2a is up-regulated by the stimulation of 1,25(OH)2D3 and is 
decreased by FGF23 and PTH (60, 78). Similarly NaPi2b expression in the intestine is 
increased by 1,25(OH)2D3 (79). It has already been shown that NaPi2a renal expression 
is increased in Fgf23 mutant mice (72) and similar results were also found in klotho 
deficient mice (80). Accelerated aging directly or indirectly depend on the 
hyperphosphatemia in experimental animals, as feeding them a low-phosphate or low-
vitamin D diet greatly expands their life span (81). The klotho deficient mice show 
excessive phosphate retention which cause hyperphosphatemia and thereby reduced 
survival (67, 68, 82-87). Age-related phenotypes of klotho deficient mice could be 
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suppressed and thereby extending lifespan by reducing phosphate burden via inhibiting 
renal NaPi2a activities by generating NaPi2a/klotho double knockout mice (86). When 
these mice were fed a with high phosphate diet these mice experienced accelerated 
aging like phenotypes, as seen in the klotho deficient mice (86, 88). The klotho deficient 
mice are infertile. Phosphate restriction of these mice regained fertility, as evidenced in 
NaPi2a/klotho double knockout mice (88). When these mice were given high phosphate 
diet, they became infertile, pointing that phosphate may affect reproductive abilities and 
thereby accelerate aging process (86).  
 
1.6.4 FGF23 and chronic kidney disease (CKD) 
 
Elevated levels of FGF23 is one of the earliest indications of abnormal bone-mineral 
metabolism in CKD (89). Serum FGF23 levels increase as a result of progressive loss 
of renal function and this level can be increased by 100-1000 fold times higher than in 
healthy controls by the time patients require dialysis (90). A recent study revealed that 
FGF23 levels increase as glomerular filtration rate (GFR) declines during the 
progression of CKD (91) and this report demonstrated that the elevation of FGF23 
develops before that of parathyroid hormone (PTH) and serum phosphate (89). Even 
though with elevated levels of FGF23, CKD patients do suffer from hyperphosphatemia 
(92). Patients with CKD can develop secondary hyperthyroidism due to failure of FGF23 
to maintain normal serum phosphate levels. However, the mechanism of increased 
FGF23 levels in patients with CKD is not fully known. Elevated FGF23 levels in patients 
with CKD could results from reduced renal clearance of FGF23 (93) and enhanced 
production of FGF23 that counteract hyperphosphatemia. This hypothesis is supported 
by phosphate loading which results in increased FGF23 levels (94). Calcitriol therapy in 
patients with CKD might also lead to increasing levels of FGF23 (95). It has been 
reported that both phosphorous and calcitriol could increase serum FGF23 levels (76). 
As elevated FGF23 levels are associated with increased excretion of phosphate and 
low vitamin D (47, 96), therefore, the elevated levels of FGF23 in patients with CKD can 
develop secondary hyperthyroidism by decreasing 1,25(OH)2D3 (96, 97). The interaction 
of FGF23 and parathyroid hormone is a complex process that has not yet been clearly 
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understood. Several studies have demonstrated that PTH stimulates FGF23 production 
(98, 99), however FGF23 was also shown to reduce PTH synthesis (100, 101). 
 
 
 
Fig. 4: Various factors involved in CKD-MBD. In advanced CKD, dietary phosphate and PTH stimulate 
FGF23 release and FGF23 decreases serum calcitriol that is which in turn secrete PTH. The higher level 
of PTH also releases low-molecular weight FGFs through parathyroid hormone receptor (PTHR) that act 
on canonical FGFRs to increase FGF23. The high FGF23 levels act on FGFRs in the heart activating 
PLCγ calcineurin contributing to the left ventricular hypertrophy (LVH) in these patients. 
Hyperphosphatemia and reduced soluble klotho are factors involved in vascular calcification of soft tissue 
of CKD patients, adapted from Silver J et al, Nephrol Dial Transplant, 2012 (102). 
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1.6.5 FGF23 and cardiovascular diseases (CVD) 
 
Elevated FGF23 levels are associated with CVD, including left ventricular hypertrophy 
(LVH), arterial stiffness, vascular calcifications, endothelial dysfunction and increased 
levels of inflammatory markers (103-107). LVH is a common cardiovascular disorder 
and the major risk factor for cardiovascular death in patients with end stage renal 
disease (ESRD) (108-110). FGF23 is associated with LVH (104). However, it is still ill-
defined, whether the effect is direct or indirect on heart. An in-vivo study has shown that 
FGF23 directly induces LVH through the activation of FGF receptors (103) and the 
effect was klotho independent, as myocardial cells do not express klotho, a co-receptor 
of FGF23. However, Agarwal et al. have shown that klotho deficient mice did not have 
LVH in comparison to 1-α hydroxylase deficient mice (111). Several other studies have 
raised question if there is a direct effect of FGF23 on the myocardium (112-114). 
Further studies are required to answer this question.  
 
1.6.6 Inflammation and oxidative stress  
 
Inflammatory markers are known risk factors for cardiovascular diseases in CKD 
patients. In vivo experiments have reported that FGF23 increases the production of 
inflammatory markers i.e lipocalin-2, TGF-β and TNF (115). It has been shown that 
FGF23 is strongly correlated  with interlukin-6, TNF-α, high-sensitivity C-reactive protein 
(hsCRP), endogenous soluble receptor of advanced glycation end products (esRAGE), 
advanced oxidation protein products (AOPP) in CKD patients (106, 116). 
 
1.6.7 FGF23 and vascular calcification 
 
Vascular calcification is the accumulation of phosphate and calcium in the blood vessels 
and soft tissue. The major factor of mortality in CKD is cardiovascular diseases and 
vascular calcification (117, 118). Accumulating evidence suggests that high serum 
phosphate levels associated with vascular calcification in CKD patients (119, 120). 
Transport of Pi by Na-dependent phosphate transporter (NaPiII) up-regulates 
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osteogenic genes and causes vascular calcification (121, 122). High serum FGF23 is 
associated with declining kidney function. Clinical observations in a several studies 
have found a positive association with serum FGF23 and vascular calcification in 
patients with CKD and ESRD (123-125)  
 
1.7 Regulation of FGF23 
 
In normal individuals, low levels of FGF23 are detected in the circulation, but levels are 
increased in response to phosphate loading, vitamin D administration, renal failure, and 
in several hereditary and acquired hypophosphatemic disorders (20, 76, 89, 126) 
 
1.7.1 Regulation by 1,25(OH)2D3  
 
1,25(OH)2D3 is the most important regulator of FGF23.  In vivo studies, have shown 
1,25(OH)2D3 increases circulating FGF23 levels. 1,25 (OH)2D3 increases the 
transcription of FGF23 in osteoblasts ⁄ osteocytes and this action is mediated by a 
vitamin D receptor (VDR), while disturbance of 1,25(OH)2D3 pathway decreases 
circulating FGF23 in mice (47, 76, 95). It has been suggested that FGF23 acts as a 
counter regulatory hormone for 1,25(OH)2D3, which maintains phosphate balance by 
vitamin D-mediated suppression of PTH and increased intestinal phosphate absorption 
(127). In the gastrointestinal tract 1,25(OH)2D3 enhances calcium and phosphate 
absorption (Fig. 5). Increases in calcium, as well as 1,25(OH)2D3 itself suppress PTH in 
the parathyroid gland, which in turn acts on the kidney and enhance renal calcium 
excretion to maintain neutral calcium balance (40, 47, 127). However, reduced PTH 
levels, limits kidney function to excrete increased phosphate absorbed from the 
gastrointestinal tract (47). FGF23 expression can be regulated by both VDR-dependent 
and VDR-independent signaling pathway. VDR null mice exhibited undetectable FGF23 
levels, pointing the importance of VDR in the regulation of FGF23 (48, 128). On the 
other hand, dietary phosphate increased FGF23 levels in VDR null mice, suggesting 
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that regulation of FGF23 is also mediated by a VDR-independent pathway (35, 36, 50, 
129).  
 
1.7.2 Regulation by phosphate 
 
The effect of dietary phosphorus on serum FGF23 levels and production by osteocytes 
⁄osteoblasts are conflicting.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5: Schematic diagram showing relationship between FGF23, vitamin D, PTH, calcium and 
phosphorus. 1,25(OH)2D3 causes suppression of PTH and increases intestinal calcium absorption. 
1,25(OH)2D3 also stimulates phosphate absorption. Regulation of FGF23 production by dietary phosphate 
in bone likely occurs through unknown intermediate steps, because hyperphosphatemia per se does not 
directly stimulate FGF23 production by osteoblasts, adapted from Liu S et al, J Am Soc Nephrol. 2006 
(47).  
 
Several observations have been shown that phosphate loading increases serum FGF23 
levels in mice and in human subjects (76, 130, 131), whereas, two other studies have 
failed to demonstrate increased in serum FGF23 levels in response to phosphate 
loading (90, 132). Phosphate restriction has been shown to decrease circulating FGF23 
levels (133). Based on current understanding it appears that the mechanism of FGF23 
regulation by phosphate may be complex and indirect.  
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1.7.3 Regulation by PTH 
 
In a mice model of primary hyperparathyroidism, FGF23 levels are increased (98), while 
decreased FGF23 has been shown after parathyroidectomy (134). PTH increased 
FGF23 mRNA levels directly in rat osteoblast-like UMR 106 cells (135). However, PTH 
failed to increase FGF23 production in ROS 17/2.8 osteoblast-like cells (47) or in 
calvarial culture (136). Patients with hypoparathyroidism (137) and PTH null mice (138) 
exhibit increased levels of FGF23. On the other hand vitamin D deficient mice display 
extremely low levels of FGF23, despite elevated levels of PTH (51, 139) and PTH null 
mice can restore FGF23 production after injection of vitamin D (47). Thus, regulation of 
FGF23 by PTH may be dependent on vitamin D.      
 
1.7.4 Regulation by bone-derived factors 
 
Bone is the main site of expression of FGF23 pointing the probability of important local 
regulators of FGF23. PHEX is expressed mainly by osteoblasts and osteocytes in bone 
(40). Increased production of FGF23 by osteocytes, has been found in a study due to 
inactivating mutations of PHEX (8), indicating that PHEX may somehow regulate the 
biosynthesis of FGF23. Initially, FGF23 was presumed to be a substrate for PHEX but 
recent findings suggest that FGF23 is not a direct substrate for PHEX, rather PHEX  
can regulate Fgf23 gene expression possibly through the action of unknown PHEX 
substrates or other downstream effectors (10). Like PHEX, dentin matrix protein (DMP) 
1 is also predominantly expressed by osteoblast and osteocytes in bone. DMP1 
regulates extracellular matrix mineralization (140). Inactivation mutation of DMP1 
displays increased FGF23 production in bone (141).  
 
1.7.5 Other regulators 
 
Recently, iron has been considered a regulator of FGF23. But still it’s role is enigmatic 
(142-146). Sympathetic nervous system is also involved in the regulation of FGF23, 
since FGF23 expression is triggered by sympathetic activation (147).  
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1.8 GSK3 signaling 
 
1.8.1 GSK3 
 
Glycogen synthase kinase-3 (GSK3) is a downstream signaling molecule of PI3K and 
PKB/Akt and is a serine/threonine protein kinase that participates in the regulation of 
glycogen metabolism (148). GSK3 was first identified as a protein kinase that 
phosphorylates and thus inactivates glycogen synthase, the key enzyme in glycogen 
biosynthesis (149). GSK3 was isolated and purified from rabbit skeletal muscle (150). 
Woodgett JR et al. have found by cloning that GSK3 has two closely related isoforms, 
GSK3α and GSK3β, which are expressed ubiquitously in mammalian tissues (151, 
152). Besides  glycogen metabolism, GSK3 has important roles in the regulation of 
cellular processes including; cell proliferation, differentiation microtubule dynamics, cell 
cycle and apoptosis (153). Aberrant GSK3 signaling plays roles in the pathophysiology 
of diabetes, cancer, inflammation, neurological disorders and cancer (154, 155).   
 
1.8.2 Regulation of GSK3 by insulin and growth factors 
 
It was first thought that inhibition of GSK3 might be the cause of insulin-induced 
dephosphorylation of glycogen synthase (156) and later on it was confirmed that insulin 
stimulates the dephosphorylation of glycogen synthase at sites where phosphorylated 
by GSK3 (157) and as a result insulin inhibits GSK3 acutely (158, 159). Well known 
mechanism through which GSK3 is inhibited by insulin results from its phosphorylation 
at Ser9 in GSK3β  and Ser21 in GSKα and that is catalyzed by PKB (160). Insulin 
stimulates PI3K which, in turn activate PKB/Akt and serum and glucocorticoid inducible 
kinase (SGK) isoforms (161, 162). In a cascade of signal transduction GSK3 is 
phosphorylated and thus inactivated by PKB (163) and SGK1 (164). By activating 
protein phosphatase insulin may stimulates dephosphorylation of glycogen synthase 
(165) (Fig. 6).  
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Fig. 6: Inhibition of GSK3 by insulin signaling pathway which regulate glycogen synthesis and 
protein synthesis. Insulin binds to its receptor and activates the intrinsic protein tyrosine kinase activity 
of the receptor. Phosphotyrosine (pY) residue interacts with insulin receptor substrate proteins 
(IRS1 and IRS2) and recruiting them to the plasma membrane. Then, insulin receptor substrate (IRS) 
interacts with p85 subunit of PI3K and recruits them to the plasma membrane. PI3K catalyses the 
formation of phosphatidylinositol-3,4,5-trisphosphate (PtdIns(3,4,5)P3) from PtdIns(4,5)P2. 
PtdIns(3,4,5)P3 binds to PDK1 and PKB/Akt, engage  them at the membrane and allowing PDK1 to 
activate PKB/Akt. Once PKB/Akt is activated, in turn, phosphorylates and inhibits GSK3, adapted from 
Cohen P et al, Nat. Rev. Mol. Cell Biol. 2001 GSK3 (148). 
 
 
1.8.3 GSK3 and sympathetic nervous activity 
 
Insulin regulates glucose metabolism. It also plays a role in renal phosphate handling 
(166). Cellular insulin effects are mediated by PI3K dependent PKB/SGK isoform 
activation (161, 162). To reveal physiological importance of PKB/SGK dependent 
regulation of GSK3, gene-targeted mice were generated in which serine residue was 
replaced by alanine (GSK3α21A/21A, GSK3ß9A/9A) within the PKB/Akt phosphorylation 
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site. GSK3α/β mice carrying this mutation make the kinase insensitive to the inhibitory 
effect of PKB/Akt. Therefore, gsk-3KI mice carrying mutations are protected from the 
inhibitory effect of insulin (167). In mice carrying these mutations (gsk-3KI), plasma 
phosphate concentration was significantly lower and urinary phosphate excretion 
significantly higher than in the corresponding wild type mice (gsk-3WT) (168). It has been 
reported that arterial blood pressure is enhanced in gsk-3KI mice as compared to wild 
type mice (169, 170) and by the treatment with α-adrenergic antagonist prazosin 
enhanced blood pressure could be lowered which indicate to having sympathetic nerve 
activity (171). Epinephrine is a marker of sympathetic nervous activity. Gsk-3KI mice 
show increased levels of plasma and urine epinephrine levels (172).  
 
1.9 Actin cytoskeleton 
 
Actin cytoskeleton is a cellular network within the cytoplasm which provides the cell 
shape, functional support and mechanical strength (173, 174), directs locomotion, 
regulates chromosome separation during mitosis and meiosis, intracellular transport of 
organelles in cells (175, 176). There are three main components of actin cytoskeleton in 
eukaryotic cells (actin microfilaments, microtubules and intermediate filaments). Actin 
microfilament is composed of monomeric (G-actin) and filamentous (F-actin) actin that 
constitute actin cytoskeleton along with ABP (actin-binding protein) (177). Actin 
microfilament consisting of highly polarized plus (barbed) end and minus (pointed) end. 
Actin exists within the cells in a dynamic transition of polymerization and 
deploymerization. At steady state F-actin grows fast at the barbed end by the adding of 
ATP-bound G-actin than does the pointed end where depolymerization occur by 
dissociation of ADP-bound G-actin. Actin can be polymerized or depolymerized by 
exchange of ATP or hydrolysis of ATP (178, 179).  
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1.9.1 Rho GTPase and actin cytoskeleton 
 
Rho GTPase is a crucial regulator in the actin signaling pathway that links extracellular 
or intracellular signals to the assembly of actin cytoskeleton. Actin reorganization, 
following the modification of actin polymerization is a cellular response initiated by 
various signals including growth factors, cytokines and hormones (Fig. 7) which transmit 
signal through Rho-family GTPase in particular Rho, Rac and Cdc42 (180, 181). Actin 
cytoskeleton dependent cellular process including cytokinesis (182), cell migration (183) 
and endo/exocytosis (184) is severely impaired during dominant negative mutation in 
Rho-GTPase. Cofilin is phosphorylated by LIM kinase which reduces its actin-binding 
activity. LIM kinase is phosphorylated by ROCK that is regulated by Rho-GTPase (185, 
186).  
 
 
 
 
 
 
  
 
 
 
 
 
 
Fig. 7: Signal transduction to the actin cytoskeleton triggers a variety of cell response. 
Extracellular stimuli lead to the activation of membrane receptors which transmits signals to the actin 
cytoskeleton by specific actin signaling molecules. Alternation of actin cytoskeleton dynamics have been 
implicated in cellular outcomes including survival, secretion, proliferation and apoptosis and motility, 
Adapted from Papakonstanti EA and Stournaras C, FEBS let, 2008(187). 
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1.9.2 Rho GTPase and PI3K 
 
Importance of PI3-kinase in cell survival and in actin restructuring has been described 
(188, 189). Rho GTPase associates with PI-kinase and control actin cytoskeleton 
reorganization. PI3K phosphorylates inisitol and forms the lipid products PIP2 and PIP3. 
These lipids then activate the signaling cascade of downstream effectors PKB/Akt or 
small GTPase Cdc42 and Rac1 (188). Rac1, in turn, promotes actin polymerization and 
changes cell morphology (190, 191)  
 
 
1.9.3 Actin cytoskeleton and diseases 
 
The dynamic reorganization of actin cytoskeleton is very crucial for cellular processes. 
During infection many pathogens hijack host cell actin cytoskeleton and disrupt 
cytoskeleton rapidly (192). Alternation in the actin cytoskeleton dynamics govern cellular 
outcomes which have been linked to human diseases, including muscular dystrophy 
(193, 194), liver diseases (195) and cancer metastasis and invasion (196, 197). Altered 
regulation of actin cytoskeleton is associated with neurological disorders and ischemic 
kidney disease. In Alzheimer’s disease deregulation of ADF/cofilin was observed (198, 
199).
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2. Aim of the study 
 
FGF23 is a phosphaturic hormone which regulates mineral homeostasis and vitamin D 
metabolism. Mice expressing PKB/Akt resistant gsk-3ki show hypophosphatemia, renal 
phosphate loss and sympathetic nervous activation. It has been reported that insulin 
dependent PI3K signaling involved in the regulation of phosphate transport. 
Phosphaturia in these mice could be due to the inhibitory effects of GSK3 on the renal 
phosphate transporter NaPi2a, but in addition, FGF23 could be involved. Sympathetic 
activation of the nervous system and vitamin D stimulate FGF23 secretion. Vitamin D 
has been implicated in actin cytoskeleton reorganization. Based on this hypothesis, the 
present study was conducted to investigate 
 
1. Whether GSK3-controlled sympathetic activity is involved in the regulation of 
FGF23 production. 
2. Whether FGF23 gene transcription is regulated by actin cytoskeleton. 
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3. Materials and methods 
 
3.1 Materials 
 
3.1.1 Chemicals and reagents 
 
Name Company name and country of origin 
1,25(OH)2D3 Enzo life science, New York, USA 
30% Acrylamide Carl Roth, Karlsruhe, Germany 
Amersham hyperfilm GE Healthcare, München, Germany 
Ammonium persulfate Sigma Aldrich, St. Louis, USA 
Anti-Klotho (rat polyclonal IgG 
antibody)      
Kyowa Hakko Kirin Co., Ltd., Japan  
Anti-GAPDH                                               Cell Signaling Technology, USA 
Anti-rabbit HRP- conjugate antibody Cell Signaling Technology, USA 
Anti-rat HRP conjugate linked 
antibody 
Cell Signaling Technology, USA 
Bradford protein assay Bio-Rad, München, Germany 
Bovine serum albumin (BSA) Carl Roth, Karlsruhe, Germany 
Chloroform Carl Roth, Karlsruhe, Germany 
Cytochalasin B TOCRIS, Bristol, UK 
Diethylether    Roth, Karlsruhe, Germany 
DMEM   Invitrogen, Darmstadt, Germany 
DTT Invitrogen, Darmstadt, Germany 
EDTA Sigma Aldrich, St. Louis, USA 
Ethanol Roth, Karlsruhe, Germany 
EGTA Sigma Aldrich, St. Louis, USA 
Enhanced chemiluminescence (ECL)       GE Healthcare, München, Germany 
FBS  Gibco, Life Technologies, Darmstadt, Germany 
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Glucose, corn sugar                                  Sigma Aldrich, St. Louis, USA   
Glycine Carl Roth, Karlsruhe, Germany 
Glycerol Carl Roth, Karlsruhe, Germany 
IPA3 Tocris, Bristol, UK 
Isopropyl alcohol Carl Roth, Karlsruhe, Germany 
Methanol    Carl Roth, Karlsruhe, Germany 
Sodium chloride (NaCl) Carl Roth, Karlsruhe, Germany 
Nitrocellulose membranes Whatman, Maidstone, UK 
Non-fat milk powder                                  Carl Roth, Karlsruhe, Germany 
NP-40 Carl Roth, Karlsruhe, Germany 
PBS PAA Laboratories, Cölbe, Germany 
Penicillin/Streptomycin                             PAA Laboratories, Cölbe, Germany 
PeqGold protein marker                           PeqLab, Erlangen, Germany 
peqGold TriFast  PeqLab, Erlangen, Germany 
PMSF Sigma Aldrich, St. Louis, USA 
Propranolol Sigma Aldrich, St. Louis, USA 
Protease inhibitor cocktail                       Roche Diagnostics, Mannheim, Germany 
PVDF  membrane ThermoScientific,Waltham,Massachusetts,USA  
Roti Loading Dye (4x) Carl Roth, Karlsruhe, Germany 
Rac1 inhibitor NSC 23766 Tocris, Bristol, UK 
Phalloidin Life Technologies, USA 
RIPA lysis buffer Cell Signaling Technology, USA 
SDS Carl Roth, Karlsruhe, Germany 
Sodiumdeoxycholate Sigma Aldrich, St. Louis, USA 
Sodium fluride Carl Roth, Karlsruhe, Germany 
Sodium pyrophosphate Sigma Aldrich, St. Louis, USA 
Sodium ortho vanadate Sigma Aldrich, St. Louis, USA 
Stripping buffer Carl Roth, Karlsruhe, Germany 
TEMED Carl Roth, Karlsruhe, Germany 
Tris-base Sigma Aldrich, St. Louis, USA 
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Trypsin-EDTA PAA Laboratories, Cölbe, Germany 
TritonX100 Carl Roth, Karlsruhe, Germany 
Tween 20 Carl Roth, Karlsruhe, Germany 
Wogonin Enzo life science 
 
3.1.2 Kits 
 
1. 1,25(OH)2D3 EIA Kit (Immunodiagnostic Systems, Boldon, UK). 
2. FGF23 (c-term) ELISA Kit (Immutopics International, California, USA). 
3. Intact FGF23 ELISA kit (Kainos Laboratories, Tokyo, Japan). 
4. Creatinin PAP,enzymatic (LT-SYS, Labor Technik, Germany). 
5. Creatinine Jaffe, Kinetic (LT-SYS, Labor Technik, Germany). 
6. Phos (inorganic phosphorus) (Roche Diagnostics, Mannheim, Germany). 
7. Mouse PTH 1-84 ELISA Kit (Immunotpics International, California, USA). 
8. Vanillylmandelic acid (VMA) ELISA Kit (IBL international, Hamburg, Germany). 
9. Epinephrine ELISA kit (LDN, Germany). 
10. SuperScript III First-Strand Synthesis kits (Invitrogen, Darmstadt, Germany). 
 
3.1.3 Equipments 
 
Name Company name and country of origin 
CFX96 real-time system Bio-Rad Laboratories, München, Germany 
BioPhotometer Eppendorf, Hamburg, Germany 
Biorad chemidoc XRS                       Bio-Rad Laboratories, München, Germany 
Electrophoresis cell                            Bio-Rad Laboratories, München, Germany 
Electrophoresis power supply            Bio-Rad Laboratories, München, Germany 
Electrophoretic transfer cell                Bio-Rad Laboratories, München, Germany 
Eppendorf centrifuge 5417c Eppendorf, Hamburg, Germany 
Eppendorf thermomixer 5436 Eppendorf, Hamburg, Germany 
ELISA plate reader (Power Wave XS2) BioTek, Winooski, VT, USA 
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Heraeus cell culture hood Thermo Fisher Scientific, Waltham MA, USA 
Heraeus cell culture incubator Thermo Fisher Scientific, Waltham MA, USA 
Homogenize rotor   Carl Roth, Karlsruhe, Germany 
Non-Invasive blood pressure amplifier   IITC life sciences, Los Angeles, USA 
pH meter Sartorius, Göttingen, Germany 
Power labs dual bio amps (ML135) ADInstruments GmbH, Germany 
Metabolic cage Techniplast, Hohenpeissenberg, Germany 
Flame photometry (ELEX 6361) Eppendorf, Hamburg, Germany 
Primus PCR instrument 25 Peqlab, Erlangen, Germany  
Zeiss LSM 5 EXCITER confocal 
microscopy 
Carl Zeiss, Germany 
               
  
3.2 Methods 
 
3.2.1 Cells 
 
Rat osteosarcoma cells UMR 106 were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM) containing 4,5 g/l glucose, supplemented 10% fetal bovine serum FBS (Gibco, 
Life Technologies, Darmstadt, Germany), 50 U/ml penicillin and 50 µg/ml streptomycin 
(Gibco, Life Technologies, Darmstadt, Germany) at 5% CO2 and 37
0 C . UMR 106 cells 
were pretreated with 100 nM 1,25(OH)2D3. After 42 h cells were treated with 100 nM 
cytochalasin B, 50 µM Rac1 inhibitor NSC 23766 and 10 μM IPA3 (TOCRIS, Bristol, 
UK), or with vehicle only for 6 h, and thereafter were harvested for RT-PCR. For some 
experiments, cells were treated with or without 150 µM propranolol (Sigma Aldrich, St. 
Louis, USA) over night (14-16 h) in the presence of 100 nM 1,25(OH)2D3. For Western 
blotting cells were treated with 100 nM 1,25(OH)2D3 for 15 min, 30 min and 24 h. For 
some experiments, cells were incubated with or without 100 µM NFκB inhibitor wogonin 
(Enzo Life Sciences, Germany) for 24 h and in addition treated with 100 nM 
1,25(OH)2D3 or with vehicle for another 15 min. Alternatively, cells were treated with 50 
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µM Rac1 inhibitor NSC 23766 and 10 µM PAK1 inhibitor IPA3 in presence or absence  
of 100 nM 1,25(OH)2D3 for 15 min. 
 
3.2.2 Quantification of mRNA expression 
 
Total RNA was isolated using peqGOLD TriFast (PeqLab Biotechnologie GmbH, 
Erlangen, Germany) reagent, a method which is based on a chloroform extraction 
protocol. The mRNA was transcribed with SuperScriptIII Reverse Transcriptase 
(Invitrogen, Darmstadt, Germany) using random hexamers (Invitrogen, Darmstadt, 
Germany). Quantitative RT-PCR was performed on a BioRad iCycler iQTM Real-Time 
PCR Detection System (Bio-Rad Laboratories, München, Germany) using the following 
primers: 
Tbp (TATA box-binding protein): 
Forward primer (5'-3'): ACTCCTGCCACACCAGCC 
Reverse primer (5'-3'): GGTCAAGTTTACAGCCAAGATTCA 
Fgf23 
Forward primer (5'-3'): TGGCCATGTAGACGGAACAC 
Reverse primer (5'-3'): GGCCCCTATTATCACTACGGAG 
 
The final volume of the PCR reaction mixture was 20 µl and contained: 2 µl cDNA, 1 µM 
of each primer, 10 µl GoTaq qPCR Master Mix (Promega, Mannheim, Germany) and 
sterile water up to 20 µl. qPCR conditions were 95°C for 3 min, followed by 40 cycles of 
95°C for 10 s and 58°C for 30 s. Calculated mRNA expression levels were normalized 
to the expression levels of Tbp of the same cDNA sample as internal reference. All 
PCRs were performed in duplicate. Relative quantification of gene expression was 
performed using the ΔΔct method. 
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3.2.3 Confocal microscopy 
  
For actin staining, UMR 106 cells were cultured on glass chamber slides (BD 
biosciences) for 24 h and treated with or without 1,25(OH)2D3  (100 nM) for 15 min, 30 
min and 24 h. After washing twice with PBS, cells were fixed with 4% PFA for 15 min at 
room temperature and then permeabilized with 0.03% Triton-X100 for 10 min. The cells 
were blocked with 3% BSA in PBST and incubated with rhodamine-phalloidin (1:200, 
Life Technologies, USA) for F-actin staining and with DRAQ-5 dye (1:3000, Biostatus, 
Leicestershire, UK) for nuclei staining for 30 min in the dark. After three washing steps, 
slides and coverslips were mounted with ProLong Gold antifade reagent (Life 
Technologies, USA). Images were taken on a Zeiss LSM 5 EXCITER confocal laser 
scanning microscope (Carl Zeiss, Germany) with a water immersion Plan-Neofluar 
40/1.3 NA DIC. 
 
3.3 Mice 
 
All animal experiments were conducted according to the German law for the welfare of 
animals and were approved by local authorities (Baden-Württemberg). Experiments 
have been performed with gene-targeted mice carrying a mutant GSK3α,β, in which the 
codon encoding Ser9 of GSK3ß gene was changed to encode nonphosphorylable 
alanine (GSK3ß9A/9A), and simultaneously the codon encoding Ser21 of GSK3α was 
changed to encode the nonphosphorylable GSK3α21A/21A thus yielding the 
GSK3α/β21A/21A/9A/9A double knock in mouse (gsk-3KI) as described previously (167). The 
mice were compared to corresponding wild type mice (gsk-3WT). In this study, I have 
used gsk-3KI mice and gsk-3WT mice. The animals were genotyped by PCR using 
standard method. If not stated otherwise, mice were fed a control diet (Altromin 1310) 
and adlib access to drinking water. 
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3.3.1 Propranolol treatment 
 
GSK3 wild type (gsk-3WT) and GSK3 knock in (gsk-3KI) mice were treated with 
propranolol at dose of 500 mg/L for 7 days in drinking water. Blood was drawn before 
and after treatment with propranolol. Mice were fed a control diet (Altronin 1310). The 
mice were studied at the age of 2-5 months. 
 
3.3.2 Blood chemistry 
 
To obtain serum or plasma, animals were lightly anesthetized with diethyl ether (Roth, 
Karlsruhe, Germany) and about 50 - 200 μl of blood were drawn by puncturing the retro-
orbital plexus with capillaries before and after treatment with β-blocker propranolol at 
the dose of 500mg/L in drinking water for one week. Serum or plasma was separated by 
centrifugation of blood at 7000 rpm for 10 min at 40C and kept at -80°c until 
measurement. 
 
3.3.3 FGF23 measurement 
 
Serum FGF23 was measured by ELISA (Immutopics International, San Clemente, USA) 
according to the manufacturer´s instructions. Briefly, for the measurement of C-term 
FGF23 25 µl standard, control or samples were loaded into the designated or mapped 
well coated with anti-FGF23. Biotinylated antibody and HRP-conjugated antibody were 
added to each well in 1:1 ratio and the plate was sealed and then covered with 
aluminium foil to avoid exposure to light. After incubation at room temperature for 3 h on 
a rotator at 180-220 rpm, wells were washed three times with washing buffer. ELISA 
HRP substrate was added to each well and incubated another half an hour. After 
incubation period, stop solution was added and reading took at 450 nm against a 
reagent blank. 
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3.3.4 Calcitriol measurement 
 
An EIA kit was employed to determine plasma concentrations of 1,25(OH)2D3 (IDS, 
Boldon, UK). All experiments have done according to the manufacturer’s instructions.  
 
 
3.3.5 Plasma PTH measurement 
 
Plasma PTH concentration was measured by using mouse PTH 1-84 ELISA kit 
(Immutopics International, San Clemente, USA). Manufacturer’s instructions were 
followed. Briefly, 20µl of plasma samples, standard and control were used into the 
designated antibody coated well. After that, mouse PTH 1-84 biotinylated antibody and 
mouse PTH 1-84 HRP conjugated antibody were added in 1:1 ratio into each well. The 
plate was covered with plate sealer and then wrapped with aluminium foil and incubated 
for 3 h at room temperature on a horizontal rotator at the speed of 180-220 rpm. Wells 
were washed five times with wash buffer and added 100 µl of ELISA HRP substrate into 
each well and incubated another half an hour. After adding ELISA stop solution into 
each of the wells, absorbance was measured by ELISA plate reader.   
 
3.3.6 Serum calcium, phosphate and creatinine 
 
Following serum parameters were measured. Serum Ca2+ was determined by flame 
photometry. Inorganic phosphate was measured by photometric method (Roche, 
Mannheim, Germany) and serum creatinine concentration by using an enzymatic 
colorimetric method (Labor & Technik, Berlin, Germany). All experiments have done 
according to the manufacturer’s instruction.  
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3.3.7 Metabolic cage study 
 
Both gsk-3KI mice and gsk-3WT mice were placed individually in metabolic cages 
(Techniplast, Hohenpeissenberg, Germany) for the collection of 24 h urine to evaluate 
renal excretion. Mice were allowed a 2-3 days habitation period and intake of food and 
drinking water, urinary flow rate and body weight were recorded regularly to make sure 
that the mice were adapted to the new environment. Subsequently, 24 h of urine was 
collected for 5 consecutive days to obtain the urinary parameters. Urine was collected 
under water-saturated oil and metabolic cages were siliconized to ensure smooth urine 
collection. After collecting base line urine mice were treated with propranolol in drinking 
water at the dose of 500 mg/L for 7 days and urine was collected. Mice were fed control 
diet. Urine aliquots were rapidly frozen and store at -80 until measurement. 
 
 
3.3.8 Urinary phosphate, calcium and creatinine 
 
The phosphate concentration was determined colorimetrically using commercial 
diagnostic kits (Roche Diagnostics, Mannheim, Germany). The urinary concentration of 
Ca2+ was measured by flame photometry (ELEX 6361, Eppendorf) or by a photometric 
method according to the manufacturer’s instructions (Dri-chem clinical chemistry 
analyzer FUJI FDC 3500i, Sysmex, Norsted, Germany). The creatinine concentration in 
urine was determined using the Jaffe reaction (LT-SYS, Labor Technik, Germany). 
 
3.3.9 Measurement of urinary vanillylmandelic acid (VMA) and epinephrine  
 
For the measurement of renal excretion both gsk-3KI mice and gsk-3WT mice were 
placed individually in the metabolic cages to adapt new environment on the first two 
days for collecting 24 h urine. Mice were again housed from day 2-day 5 of propranolol 
treatment. Small amount of 6N HCL were added to the urine collection tube to acidify 
the urine and next 24 h acidic urine was collected. To ensure smooth urine collection, 
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metabolic cages were siliconized and urine was collected under water-saturated oil. 
Urinary epinephrine (Labor Diagnostika Nord, Nordhorn, Germany) and vanillylmandelic 
acid (IBL international, Hamburg, Germany) concentration were determined by using 
ELISA kits  
 
3.4 Blood pressure measurement 
 
The arterial blood pressure was determined by a non-invasive tail-cuff system (IITC life 
Science, Woodlands Hills, CA, USA). To get the systolic blood pressure of mice, I took 
average of several days readings for the respective mouse. To reduce the stress of 
mice some precautions were taken. Mice were placed in clean plastic animal holder. 
Before taking reading mice were given proper training. Tail of the mouse was positioned 
inside a tail cuff with a photoelectric sensor.  We determined systolic blood pressure 
before and after treatment with β-blocker propranolol. All recordings and data analysis 
were obtained by using a computerized data acquisition system and software 
(PowerLab 4/26). 
 
3.5 Measurement of F/G actin ratio by Triton X-100 fractionation 
 
For measurements of the monomeric (Triton soluble) and polymerized (Triton insoluble) 
actin, UMR 106 cells were incubated for different time points with or without and/or with 
vitamin D (100 nM), wogonin (100 µM), Rac1 inhibitor NSC 23766 (50 µM) and PAK 
inhibitor IPA3 (10 µM) where indicated. Then, cells were harvested. Actin cytoskeleton 
determination by Triton X-100 was described previously (200). Briefly, cells were 
incubated with 130 µl of Triton extraction buffer containing (0.3% TritonX-100, 5 mM Tris, 
pH 7.4, 2 mM EGTA, 300 mM sucrose, 2 µM phalloidin, 1 mM PMSF, 10 µg/ml leupeptin, 
20 µ/ml aprotinin, 1 mM sodium orthovanadate, and 50 mM NaF for 5-7 min on ice. The 
supernatant (G-actin) containing soluble protein was removed. The Triton insoluble 
fraction remaining on the culture plate was scraped and lysed with RIPA buffer (Cell 
Signaling, Frankfurt, Germany). An equal amount of protein of each fraction was subjected 
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to 10% SDS-PAGE. The proteins were transferred onto PVDF membranes which were 
then blocked with 5% nonfat dry milk powder in TBS-T for 1 h at room temperature. Next, 
the membrane was incubated overnight at 4°C with pan-actin primary antibody (1:1000 in 
5% BSA with TBS-T, Cell Signaling) and washed 3-5 times with TBS-T. Then, incubation 
with secondary anti-rabbit horseradish peroxidase-conjugated antibody was carried out for 
1 h at room temperature (1:2000; Cell Signaling). Blots were developed by commercial 
ECL (Thermo Scientific) or home made ECL reagent and band intensities were quantified 
by chemidoc Quantity one software. 
 
3.6 Western blotting 
 
To determine protein abundance, mice were anesthetized with diethyl ether. The 
kidneys were removed and immediately snap-frozen in liquid nitrogen. The kidneys of 
mice were homogenized with an electric homogenizer at 4°C on ice in lysis buffer (54.6 
mM HEPES, 2.69 mM Na4P2O7, 360 mM NaCl, 10% [vol/vol] Glycerol, 1% [vol/vol] 
NP40) or RIPA (Cell signalling) containing phosphatase and protease inhibitors 
(Complete mini, Roche, Mannheim, Germany). Homogenates were kept on ice for 30 
minutes and homogenates were centrifuged at 14000 rpm for 30 min at 40C. Protein 
concentration was quantified by Bradford protein assay (Bio-Rad, München, Germany). 
40 µg tissue lysate was separated by SDS-PAGE (8% Tris-Glycine), transferred to 
PVDF membranes (Thermo scientific, Germany), blocked for 1 h in blocking buffer (5% 
fat-free milk in Tris-buffered saline (TBS) containing 0.1% Tween), and incubated 
overnight at 40c with rat anti-klotho (1:1000 in 5% fat free milk in TBST; kindly provided 
by Akiko Saito, Kyowa Hakko Kirin Co., Ltd., Japan) antibody. After incubation with a 
horseradish peroxidase-conjugated anti-rat or anti rabbit secondary antibody (1:2000 in 
5% fat free milk in TBST; Cell Signaling, Freiburg, Germany), the bands were visualized 
with enhanced chemiluminescence according to the manufacturer's instructions or by 
using home-made ECL solution. For loading control, the membrane was probed with 
GAPDH antibody (1:2000 in 5% BSA in TBST; Cell Signaling, Frankfurt Germany). 
Densitometric analysis of klotho was performed using Quantity One software (Bio-Rad 
Laboratories). 
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3.6.1 Solutions  
Table 1. Running buffer (10X) 
Tris base 250 mM 
Glycine 1.9 M 
SDS 1% 
dH2O Up to 1 litre 
 
 
Table 2. Transfer buffer (10X) 
Tris base 198 mM 
Glycine 1.5 M 
dH2O Up to 1 litre 
 
 
Table 3. TBS (10X) 
Tris base 200 mM 
NaCl 1.3 M 
dH2O Up to 1 litre, pH 7.6 
 
 
Table 4. Solution A for ECL (200 ml) 
Tris (0.1 M) 2.42 g 
Luminol 50 mg 
dH2O 200 ml 
Adjust pH 8.6 
 
Table 5. Solution B for ECL (10 ml) 
Para hydroxyl cumeric acid 11 mg 
DMSO 10 ml 
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Table 6. Working solution for ECL 
Solution A 1 ml 
Solution B 100 µl 
Hydrogen peroxide (H2O2) 0.3 µl 
 
 
3.7 Statistics 
 
Data are provided as means ± SEM, n represents the number of independent 
experiments. All data were tested for significance using unpaired Students t-test or 
ANOVA. Only results with p < 0.05 were considered statistically significant.
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4. Results 
 
Part 1 Results 
 
4.1.1 Enhanced serum FGF23 in gsk-3KI mice 
 
It has been shown that gsk-3KI mice suffer from hypophosphatemia and renal phosphate 
wasting as well as low serum levels of 1,25(OH)2D3 (168). FGF23 is derived from bone 
and exerts its phosphate wasting effect in the kidney and thereby reduces serum 
phosphate. Thus, the serum C-terminal FGF23 and intact FGF23 concentration was 
measured. Both C-terminal FGF23 and intact FGF23 were significantly higher in gsk-3KI 
mice compared to gsk-3WT mice (Fig. 8). 
 
 
 
Fig. 8: The serum FGF23 level is elevated in gsk-3
KI 
mice compared to gsk-3
WT 
mice. 
Arithmetic means ± SEM of the serum C-terminal FGF23 (A; n=5) and intact FGF23 (B; n=6) concentration 
determined in gsk-3
WT
 mice (white bars) and gsk-3
KI
 mice (black bars). * p<0.05, **p<0.01. 
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4.1.2 Renal klotho abundance in gsk-3KI mice 
 
FGF23 binds to its receptor to exert renal function. FGFR receptor requires α-klotho as 
a co-receptor. It has been reported that reduced expression of α-klotho is associated 
with high serum concentration of FGF23 (201) in klotho knock out mice. Therefore, 
renal abundance of klotho was determined by Western blotting. I did not find any 
difference in renal α-klotho expression between the genotypes (Fig. 9). Hence, α-klotho 
does not account for elevated serum FGF23 in gsk-3KI mice. 
 
 
 
Fig. 9: Renal α-Klotho abundance in gsk-3
KI 
mice and gsk-3
WT 
mice. 
A. Original Western blots demonstrating renal Klotho (upper panel) and GAPDH (lower panel) abundance. 
B. Densitometric analysis of the Western Blot. Arithmetic means ± SEM (n = 6). 
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4.1.3 Sympathetic nervous activity in gsk-3KI mice 
 
Recently, it has been reported that sympathetic activation is a trigger of FGF23 release 
(147). Epinephrine and norepinephrine are the neurotransmitters of sympathetic 
nervous system (202). Vanillylmandelic acid (VMA) is an end-stage metabolite of the 
catecholamines, epinephrine and norepinephrine. Therefore, urinary VMA is a 
biomarker of sympathetic activation. To this end, I determined urinary epinephrine and 
VMA excretion by ELISA. In keeping with a previous report (172), I found significantly 
higher urinary epinephrine and VMA excretion in gsk-3KI mice compared to gsk-3WT 
mice (Fig. 10), which indicating increased activity of the sympathetic nervous system in 
gsk-3KI mice. 
 
Fig. 10: Enhanced urinary excretion of epinephrine and vanillylmandelic acid (VMA) in gsk-3
KI 
mice 
compared to gsk-3
WT 
mice. 
Arithmetic means ± SEM (n = 7) of the urinary 24 h-epinephrine (A) and 24 h-VMA (B) excretion of gsk-3
WT
 
mice (white bar) and gsk-3
KI
 mice (black bar). * p<0.05, ** p<0.01.  
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4.1.4 High blood pressure in gsk-3KI mice  
 
In the next series of experiments, systolic blood pressure was measured in gsk-3kI mice 
and gsk-3WT mice by tail-cuff method. As a consequence of higher sympathetic nerve 
activation, blood pressure was significantly higher in gsk-3kI mice compared to gsk-3WT 
mice. β-blocker propranolol treatment significantly reduced blood pressure of gsk-3KI 
mice to the level of gsk-3WT mice (Fig. 11). 
 
Fig. 11: β-blocker propranolol lowers systolic blood pressure in gsk-3
KI 
mice. 
Arithmetic means ± SEM of systolic blood pressure (n=12) in gsk-3
WT
 mice (white bars) and gsk-3
KI
 mice 
(black bars) determined before (left bars) and after one week of treatment with β-blocker propranolol (500 
mg/L) (right bars). *** (p<0.001) indicate significant difference between the genotypes, ### (p<0.001) 
indicates significant difference from the absence of propranolol treatment. 
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4.1.5 Glomerular filtration rate (GFR) 
 
As blood pressure may influence glomerular filtration rate of kidney (GFR), I measured 
creatinine clearance to determine GFR. Before propranolol treatment GFR was 
significantly higher in gsk-3KI mice than in gsk-3wt mice. Propranolol reduced GFR 
between the genotypes, a difference not reaching statistical significance (Fig. 12). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 12: Effects of β-blocker propranolol on GFR in gsk-3
KI 
mice. 
Arithmetic means ± SEM of GFR (n=19) in gsk-3
WT
 mice (white bars) and gsk-3
KI
 mice (black bars) 
determined before (left bars) and after one week of treatment with β-blocker propranolol (500 mg/L) (right 
bars). * (p<0.05) indicates significant difference between the genotypes. 
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4.1.6 β-blocker propranolol normalized enhanced production of FGF23 in gsk-3kI 
mice 
Next, I investigated whether sympathetic activation is responsible for increased FGF23 
production and leads to phosphaturia in gsk-3KI mice. To verify this, gsk-3KI mice and 
gsk-3WT mice were treated with β-blocker propranolol for one week at dose of 500 mg/L 
in drinking water. The serum C-terminal FGF23 concentration was significantly higher in 
gsk-3KI mice compared to gsk-3WT mice before propranolol treatment (Fig. 13). Elevated 
serum C-terminal FGF23 in gsk-3KI mice was reduced significantly by β-blocker 
propranolol treatment (500 mg/L) and abrogated the difference in serum FGF23 
between the genotypes (Fig. 13). Serum intact FGF23 was also significantly higher in 
gsk-3KI mice than in gsk-3WT mice. Propranolol treatment also reduced intact FGF23 in 
lesser extent and mimics the difference between the genotypes (Fig. 14). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 13: β-blocker propranolol reduces the serum C-term FGF23 level in gsk-3
KI 
mice. 
 Arithmetic means ± SEM of the serum C-terminal FGF23 (n=20) concentration in gsk-3
WT
 mice (white bars) 
and gsk-3
KI
 mice (black bars) measured before (left bars) and after one week of treatment with β-blocker 
propranolol (500 mg/L) (right bars). *** (p<0.001) indicate significant difference between the genotypes, ## 
(p<0.01) indicates significant difference from the absence of propranolol treatment. 
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Fig. 14: Effects of β-blocker propranolol on the serum intact FGF23 level in gsk-3
KI 
mice 
Arithmetic means ± SEM of the serum intact FGF23 (n=12) concentration in gsk-3
WT
 mice (white bars) and 
gsk-3
KI
 mice (black bars) measured before (left bars) and after one week of treatment with β-blocker 
propranolol (500 mg/L) (right bars). * (p<0.05) indicates significant difference between the genotypes. 
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4.1.7 The effect of propranolol on Fgf23 gene transcription in UMR 106 
cells 
These data suggests that sympathetic nervous activation is responsible for elevated 
FGF23 levels in gsk-3KI mice. In a recent study, Kawai M et al, have shown that β-
receptor agonist isoproterenol up-regulates Fgf23 gene transcription in UMR 106 cells 
(147). Thus, to define the molecular mechanism, UMR 106 osteoblast-like cells were 
treated with β-blocker propranolol overnight (14 h) to determine whether propranolol 
affects Fgf23 gene transcription by qRT-PCR. Overnight incubation with 150 µM 
propranolol significantly down regulated Fgf23 mRNA transcription compared to control 
cells (Fig. 15). Thus, propranolol inhibits FGF23 formation both in vivo and in vitro. 
 
Fig. 15: β-blocker propranolol down-regulates Fgf23 transcription in UMR 106 cells. 
 Arithmetic means ± SEM of Fgf23 mRNA expression in UMR 106 cells treated with or without 150 µM 
propranolol for 16 h in the presence of 1,25(OH)2D3 (n=15) Ctr. (white bars) and Propranolol (black bars). * 
(p<0.05) indicates significant difference from the absence of propranolol treatment. 
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4.1.8 Reduced 1,25(OH)2D3 in gsk-3
KI mice 
 
FGF23 down-regulates renal 1α hydroxylase (Cyp27b1), key enzyme responsible for 
active vitamin D (1,25(OH)2D3) synthesis and up-regulates 25-hydroxyvitamin D 24-
hydroxylase (Cyp24a1) thus reducing the formation and enhancing the inactivation of 
1,25-dihydroxyvitamin D3 (1,25(OH)2D3). Therefore, the serum 1,25(OH)2D3 
concentration was measured by ELISA. As expected, elevated serum levels of FGF23 
was paralleled by low serum levels of 1,25(OH)2D3 in gsk-3
KI mice before propranolol 
treatment. However, propranolol treatment did not change the serum 1,25(OH)2D3 
concentration (Fig. 16). 
 
Fig. 16: Effects of β-blocker propranolol on the serum calcitriol level in gsk-3
KI 
mice. 
Arithmetic means ± SEM of 1,25(OH)2D3 (n=11-12) concentration in gsk-3
WT
 mice (white bars) and gsk-3
KI
 
mice (black bars) measured before (left bars) and after one week of treatment with β-blocker propranolol 
(500 mg/L) (right bars). * (p<0.05) indicates significant difference between the genotypes. 
 
 
Results 
 
 
44 
 
4.1.9 Hypophosphatemia and phosphaturia in gsk-3KI mice 
 
High serum FGF23 inhibits tubular phosphate and increases renal phosphate wasting 
(phosphaturia). Therefore, I measured serum phosphate and renal phosphate excretion 
before and after treatment with propranolol. Consistent with previous reports (168), we 
found serum phosphate was significantly lower in gsk-3KI mice compared to gsk-3WT 
mice before treatment with propranolol (Fig. 17A). In spite of low serum phosphate 
(Hypophosphatemia), gsk-3KI mice had significantly higher renal phosphate excretion 
than gsk-3WT mice before propranolol treatment (Fig. 17B). I treated gsk-3KI mice and 
gsk-3WT mice with propranolol for one week in drinking water (500 mg/L). Propranolol 
treatment significantly alleviated hypophosphatemia of gsk-3KI mice (Fig. 17A) and at 
the same time reduced renal phosphate excretion (Fig. 17B). Interestingly, treatment 
with β-blocker propranolol significantly increased the serum phosphate level and 
decreased renal phosphate excretion in gsk-3WT mice (Fig 17). 
 
Fig. 17: β-blocker propranolol decreases the renal phosphate wasting of gsk-3
KI 
mice. 
Arithmetic means ± SEM of the serum phosphate concentration (A; n=19) and renal phosphate excretion (B; 
n=19) in gsk-3
WT
 mice (white bars) and gsk-3
KI
 mice (black bars) measured before (left bars) and after one 
week of treatment with β-blocker propranolol (500 mg/L) (right bars). *,** (p<0.05, p<0.01) indicate significant 
difference between the genotypes, #,### (p<0.05, p<0.001) indicate significant difference from the absence 
of propranolol treatment. 
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4.2.1 Hypoparathyroidism in gsk-3KI mice 
 
PTH inhibits renal tubular phosphate reabsorption in the kidney. Therefore, 
phosphaturia could be caused by suppressing renal phosphate reabsorption by PTH. 
PTH also regulates calcium and vitamin D. Therefore, I measured plasma PTH levels in 
gsk-3KI mice and gsk-3WT mice by ELISA before and after treatment with propranolol 
(500 mg/L). In the line with a previous report (168), I found low plasma PTH levels in 
gsk-3KI mice compared to gsk-3WT mice. However, propranolol treatment did not affect 
plasma PTH concentration (Fig. 18). 
Fig. 18: Effects of β-blocker propranolol on the plasma PTH level in gsk-3
KI 
mice. 
Arithmetic means ± SEM of PTH (n=11-12) concentration in gsk-3
WT
 mice (white bars) and gsk-3
KI
 mice 
(black bars) measured before (left bars) and after one week of treatment with β-blocker propranolol (500 
mg/L) (right bars). * (p<0.05) indicates significant difference between the genotypes 
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4.2.2 Calciuria in gsk-3KI mice 
 
Gsk-3KI mice have been reported to suffer from calciuria (168). In the next series of 
experiments, I explored whether propranolol influences serum calcium and renal 
calcium wasting in gsk-3KI mice and gsk-3WT mice. Prior to propranolol treatment I did 
not find any difference between gsk-3KI mice and gsk-3WT mice in serum calcium 
concentration (Fig. 19A). However, renal calcium excretion was higher in gsk-3KI mice 
compared to gsk-3WT mice (Fig. 19B). Propranolol treatment had no effects on serum 
calcium concentration in both genotypes. But propranolol significantly reduced renal 
calcium excretion (calciuria) in gsk-3KI mice (Fig. 19B). At the same time, renal calcium 
excretion moderately enhanced in gsk-3WT mice by the treatment with propranolol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 19: β-blocker propranolol decreases the renal calcium excretion of gsk-3
KI 
mice. 
Arithmetic means ± SEM of the serum calcium concentration (A; n=16-17) and renal calcium excretion (B; 
n=19) in gsk-3
WT
 mice (white bars) and gsk-3
KI
 mice (black bars) measured before (left bars) and after one 
week of treatment with β-blocker propranolol (500 mg/L) (right bars). *(p<0.05) indicates significant 
difference between the genotypes, # (p<0.05) indicates significant difference from the absence of propranolol 
treatment. 
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Part 2 Results 
 
4.3 The effect of 1,25(OH)2D3 on actin cytoskeleton reorganization in UMR 106 
cells 
 
This study addressed the role of the organization of the actin cytoskeleton in Fgf23 
transcription in UMR 106 osteoblast-like cells. 1,25(OH)2D3 is a well known stimulator of 
FGF23 formation. In the first series of experiments, UMR 106 cells were incubated with 
1,25(OH)2D3 (100 nM) and analyzed the changes in the actin cytoskeleton by Western 
blotting and confocal imaging. Fig. 20A and 20B illustrate that treatment with 
1,25(OH)2D3 resulted in a polymerization of the actin cytoskeleton in UMR 106 cells as 
indicated by a decrease of the G-actin over F-actin ratio. This effect was evident upon 
15 min treatment (Fig. 20A) and persisted for at least 24 h (Fig. 20B), indicating an early 
but persistent effect of 1,25(OH)2D3  on actin reorganization. 
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Fig. 20: 1,25(OH)2D3 induces polymerization of the actin cytoskeleton in UMR 106 cells. 
A: Original Western blot demonstrating G-actin and F-actin abundance in UMR 106 cells left untreated 
(Ctr.) or treated for 15 or 30 min with 1,25(OH)2D3 (100 nM). Lower panel: Arithmetic means ± SEM (n=6) 
of the ratio of filamentous (F) over soluble (G) actin in UMR 106 cells. 
B: Original Western blot demonstrating G-actin and F-actin abundance in UMR 106 cells left untreated 
(Ctr.) or treated for 24 h with 1,25(OH)2D3 (100 nM). Lower panel: Arithmetic means ± SEM (n=15) of the 
ratio of filamentous (F) over soluble (G) actin in UMR 106 cells. *p ˂ 0.05. 
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Confocal microscopy imaging also fully supported these findings and demonstrated a 
profound effect of 1,25(OH)2D3 on actin cytoskeleton reorganization with the formation 
of stress fibers (Fig. 21). 
Fig. 21: Confocal microscopy image illustrating 1,25(OH)2D3-induced actin stress fiber 
formation in UMR 106 cells. 
Confocal microscopy images demonstrating actin staining (upper images), nucleus staining (middle 
images) or the merged staining (lower images) in UMR 106 cells left untreated or treated with 
1,25(OH)2D3 (100 nM) for 15 min, 30 min, or 24 h (n=3). 
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4.4 1,25(OH)2D3-induced actin polymerization is abolished by NF-κB inhibitor 
wogonin 
Recently, it has been demontrated that proinflamatory cytokines are involved in the 
release and expression of Fgf23 which is transcription factor NF-κB dependent (203). 
On the other hand, NF-κB signaling has been shown to be involved in TNFα (204) and 
steroid hormones (205)-induced actin reorganization in various cell models. Therefore, 
in order to test whether inhibition of FGF23 expression by NF-κB inhibition also affects 
actin cytoskeleton I analyzed Western blot. As illustrated in (Fig. 22) NF-κB inhibitor 
wogonin (100 µM) totally blocked 1,25(OH)2D3-induced polymerization of actin 
cytoskeleton. 
 
 
 
 
 
 
 
 
  
  
 
 
 
 
 
Fig. 22: 1 NF-κB inhibitor wogonin blocked 1,25(OH)2D3-induced actin polymerization in UMR 106 
cells 
Original Western blot showing G-actin and F-actin abundance in UMR 106 cells left untreated (Ctr.) or 
treated for 15 min with 1,25(OH)2D3 (100 nM) in the presence or absence of NF-κB inhibitor wogonin (100 
µM).  Arithmetic means ± SEM (n=6) of the ratio of filamentous (F) over soluble (G) actin in UMR 106 
cells (lower panel). ** p<0.01, ## indicates significant difference from 1,25(OH)2D3 alone (p<0.01). 
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4.5 The effect of cytochalasin B on Fgf23 mRNA expression 
 
Cytochalasin B is a mycotoxin which block actin polymerization. Therefore, the effect of 
cytochalasin B on the mRNA expression of Fgf23 was analyzed by qRT-PCR. As shown 
in (Fig. 23), 1,25(OH)2D3-induced up-regulation of Fgf23 gene transcription largely 
inhibited when cells were incubated with cytochalasin B (100 nM) for 6 h that block actin 
reorganization. 
 
Fig. 23: 1,25(OH)2D3-induced Fgf23  transcription is inhibited by actin-disrupting agent 
cytochalasin B.  
Arithmetic means ± SEM (n = 6) of Fgf23 mRNA expression in UMR 106 cells following a 6 h treatment 
with vehicle alone or with 1,25(OH)2D3 (100 nM) without or with cytochalasin B (100 nM). ** p<0.01, # 
indicates significant difference from 1,25(OH)2D3 alone (p<0.05). 
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4.6 Rac1 and PAK1 inhibitor blocked 1,25(OH)2D3-induced Fgf23 mRNA 
expression 
 
This result reveals the role of actin cytoskeleton in FGF23 transcription regulation. Rac1 
regulates actin cytoskeleton restructuring (206). To elucidate underlying mechanism I 
treated UMR 106 cells with a Rac1 inhibitor NSC 23766 (50 µM) that blocks actin 
polymerization and Fgf23 transcript levels were determined. As illustrated in Fig. 24A, 
1,25(OH)2D3 stimulated up-regulation of Fgf23 gene transcription significantly 
decreased by Rac1 inhibitor. Rac1 has been known to activate downstream PAK1, 
which in turn regulate actin cytoskeleton reorganization. As shown in Fig. 24B, PAK 
inhibitor IPA3 (10 µM) treatment was followed by a significant decrease of Fgf23 
transcription to control levels, further implies that Rac1 controlled actin reorganization is 
directly involved in 1,25(OH)2D3-induced modulation of Fgf23 gene transcription.  
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Fig. 24: 1,25(OH)2D3-induced Fgf23 transcription is inhibited by Rac1 and PAK1 inhibitors. 
A: Arithmetic means ± SEM (n=7) of Fgf23 mRNA abundance in UMR 106 cells following a 6 h treatment 
with vehicle alone or with 1,25(OH)2D3 (100 nM) without or with Rac1 inhibitor NSC 23766 (50 µM). 
B: Arithmetic means ± SEM (n=6) of Fgf23 mRNA abundance in UMR 106 cells following a 6 h treatment 
with vehicle alone or with 1,25(OH)2D3 (100 nM) without or with PAK1 inhibitor IPA3 (10 µM). 
*, *** p<0.05, p<0.001 #, ### indicate significant difference from 1,25(OH)2D3 alone (p<0.05, p<0.001). 
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Rac1 inhibitor blocked 1,25(OH)2D3-induced actin polymerization (Fig. 25), suggesting 
that actin restructuring via polymerization upon 1,25(OH)2D3 treatment could control 
Fgf23 gene transcription in UMR 106 cells. On the other hand, the effect of IPA3 was 
moderate and did not reach to the statistical significance (Fig. 25 ). 
 
Fig. 25: 1,25(OH)2D3-induced actin polymerization is blocked by Rac1and PAK1 inhibitors 
Original Western blot illustrating G-actin and F-actin abundance in UMR 106 cells left untreated (Ctr.) or 
treated for 15 min with 1,25(OH)2D3 (100 nM) without or with PAK1 inhibitor IPA3 (10 µM) or with Rac1 
inhibitor NSC 23766 (50 µM). Lower panel: Arithmetic means ± SEM (n=5) of the ratio of filamentous (F) 
over soluble (G) actin in UMR 106 cells. * p<0.05 # indicates significant difference from 1,25(OH)2D3 
alone (p<0.05). 
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5. Discussion 
 
The present observations reveal that protein kinase B (PKB/Akt)-sensitive GSK3 is critical 
for the formation of FGF23 by regulating the activity of the sympathetic nervous system 
and further demonstrated that the role of actin cytoskeleton on the formation of FGF23 
in the UMR 106 osteoblastic cells. 
 
In this study, I analyzed gsk-3KI mice and compared with corresponding wild type mice. 
GSK3 is a downstream signaling molecule of PI3K signaling pathway. It is serine-
threonine kinase which is phosphorylated and thus, inactivated by insulin through 
PKB/Akt/SGK signaling. Gsk-3KI mice carrying a GSK3α/β mutation that makes the kinase 
insensitive to the inhibitory effect of PKB/Akt (gsk-3KI mice), as a result, it is not 
phosphorylated by either PKB/Akt or SGK1. Though inactivation of GSK3 is mediated by 
the action of insulin through PI3K/PKB/Akt-dependent mechanism, gsk-3KI mice are 
viable and do not suffer from insulin resistance and insulin action on muscle glycogen 
synthase is abolished in gsk-3KI mice (167). However, gsk-3KI mice have previously 
been reported to suffer from phosphaturia, calciuria and lower bone density (168). 
These effects were in part due to a direct inhibitory effect of GSK3 on the main 
phosphate transporter of the kidney, NaPiIIa and reduced activity of phosphate 
transporter in gsk-3KI mice (168). These results further provide evidence that the renal 
phosphate wasting of gsk-3KI mice may be in addition because of the elevated serum 
FGF23 level in these mice, as FGF23 is a phosphatonin and it inhibits renal phosphate 
reabsorption by reducing phosphate transporter (NaPi2a) and causes phosphaturia.  
 
FGF23 ELISA was employed to measure either C-terminal FGF23 or only intact FGF23. 
Intact FGF23 is the biologically active form of FGF23. The C-terminal FGF23 is a 
inactive form and results from furin-dependent degradation of intact FGF23 (207). In this 
study, both the C-terminal and intact FGF23 concentrations were measured by using 
ELISA kits. I found that both C-terminal and intact FGF23 is elevated in gsk-3KI mice as 
compared to gsk-3WT mice. 
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FGF23 binds to its receptor (FGFR) to exert its renal function. It requires α-klotho as a 
co-receptor. Klotho deficiency is associated with elevated serum FGF23 level (201). It 
suggests that klotho can act as a regulator of FGF23. Therefore, I determined renal 
klotho expression. However, I did not find any difference between the genotype. Thus, 
pointing that klotho is not relevant for enhanced serum FGF23 in gsk-3KI mice. 
The neurotransmitter epinephrine and norepinephrine are biomarkers for sympathetic 
nerve activity. Gsk-3KI mice exhibit higher sympathetic nerve activation than in gsk-3WT 
mice. Consequently, the gsk-3KI mice suffer from high blood pressure and they have 
higher heart rate as well than gsk-3WT mice (172). In this study, I could confirm 
enhanced sympathetic activation of gsk-3KI mice compared to gsk-3WT by detecting 
urinary epinephrine and VMA as a measure of sympathetic nervous activation. I found 
significantly higher 24 h urinary excretion of epinephrine and VMA in gsk-3KI mice than 
in gsk-3KI mice. VMA is the main metabolite of epinephrine and norepinephrine. Since, it 
has recently been shown that sympathetic activation to induce FGF23 release; I aimed 
to define the role of the higher sympathetic activity for enhanced production of FGF23 in 
gsk-3KI mice. Therefore, I treated gsk-3KI mice and gsk-3WT mice with the widely used β-
blocker propranolol in drinking water for one week (500 mg/L) and analyzed the 
consequence for serum FGF23 and phosphate metabolism. One week treatment with 
propranolol markedly reduced serum FGF23 level of gsk-3KI mice to the level of gsk-3WT 
mice. Therefore, enhanced sympathetic activation accounted for the excess FGF23 
formation of gsk-3KI mice. Treatment with β-blocker propranolol reduced blood pressure 
in gsk-3KI mice and abrogated the difference between the genotypes, suggesting that 
hypertension of gsk-3KI mice was because of enhanced sympathetic nervous activity, 
since propranolol treatment significantly reduced blood pressure.  Similarly, β-blocker 
propranolol treatment inhibits fgf23 mRNA expression in UMR 106 osteoblast-like cells. 
As a consequence of reduced serum FGF23 level by propranolol treatment, both the 
hypophosphatemia and phosphaturia of gsk-3KI mice were ameliorated by β-blocker 
treatment. The data presented here provide strong evidence that the renal phosphate 
wasting of gsk-3KI mice was, at least in part, the direct effect of elevated serum FGF23 
concentration. FGF23 and PTH are the main regulators of 1,25(OH)2D3. Treatment with 
propranolol did not affect the low serum 1,25(OH)2D3 level in gsk-3
KI mice despite its 
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profound effect on FGF23. However, the other main regulator of 1,25(OH)2D3 is PTH 
which stimulates 1,25(OH)2D3 formation, was also low in gsk-3
KI mice compared to gsk-
3WT mice and not significantly affected by propranolol, an effect likely to contribute to 
their low serum 1,25(OH)2D3 concentration. Apart from this, GSK3 signaling may 
influence directly on vitamin D metabolism or VDR signalling. Recently, it has been 
published that mice treated with GSK3 inhibitor lithium chloride increased serum FGF23 
concentration and decreased serum 1,25(OH)2D3 concentration (208). To rule out the 
direct effects of GSK3 on vitamin D metabolism further research is needed. 
 
In keeping with previous reports, I found that glomerular filtration rate (GFR) was 
significantly higher in gsk-3KI mice compared to gsk-3WT mice (171). β-blocker 
propranolol reduced blood pressure of gsk-3KI mice. Blood pressure lowering effect of 
propranolol may affect glomerular filtration rate (GFR). Therefore, I measured GFR after 
treatment with propranolol. The effect of β-blocker to lower blood pressure was 
associated with decline GFR in gsk-3KI mice too. This results indicating that mild 
reduction of phosphaturia and calciuria in gsk-3KI mice following propranolol treatment 
was, at least in part, also because of decline of GFR. 
 
β-blockers such as propranolol are a widely prescribed class of drugs all over the world. 
It is used for the treatment of hypertension, heart failure and atrial fibrillation (209-211). 
It is tempting to speculate that the FGF23-lowering effect of β-blockers observed in gsk-
3KI mice may have an implication for millions of patients treated with β-blockers. These 
drugs clearly reduce the cardiovascular mortality of high-risk patients. Interestingly, a 
high FGF23 level also positively correlates with cardiovascular mortality (103, 104, 107). 
Therefore, it appears possible that the benefit of β-blocker therapy is at least in part also 
related to its ability to lower the blood FGF23 concentration. Clearly, further studies are 
needed to test this hypothesis. 
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Fig. 26: GSK3-controlled sympathetic activity in FGF23 production: Insulin phosphorylates and 
inhibits GSK3. In gsk-3
KI
 mice serine residue was replaced by alanine. Thus, GSK3α/β
21A/21A/9A/9A 
renders 
the kinase insensitive to the inhibitory effects of insulin. Gsk-3
KI
 mice have higher sympathetic nervous 
activity and elevated FGF23 levels which leads to phosphaturia. β-blocker propranolol normalized 
elevated FGF23 and reduced phosphaturia. 
   
In second part of the study I investigated the role of reorganization of actin cytoskeleton 
in the regulation of FGF23 formation in UMR 106 osteoblast-like cells. The present 
observations reveal an impact of reorganization of actin cytoskeleton is required for the 
production of FGF23 as actin microfilament disrupting agent cytochalasin B blocked 
transcription of the Fgf23 gene. Here, this study demonstrated that stimulation of FGF23 
formation with 1,25(OH)2D3 resulted in actin polymerization. Furthermore, the effect of 
1,25(OH)2D3 on the reorganization of actin was blocked by NF-κB inhibitor wogonin (100 
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µM) that suppressed Fgf23 mRNA expression. During early and / or late actin 
reorganization, actin polymerization is induced by various signals including hormones 
(212), growth factors and cytokines (213, 214) and ions (215). 1,25(OH)2D3 is a known 
trigger for Fgf23 expression. FGF23 is also stimulated by NF-κB signalling (203, 216). It 
has been shown previously that both 1,25(OH)2D3  and NF-κB (217) plays a vital role in 
actin reorganization. 1,25(OH)2D3  is implicated in osteoblast maturation, matrix 
calcification and overall bone metabolism (218). These results provide novel mechanistic 
evidence for 1,25(OH)2D3-induced regulation of Fgf23 gene transcription by revealing the 
involvement of the actin specific Rac1 and PAK1 signaling. As NF-κB has an implication 
on actin polymerization, in a series of experiments, I used NF-κB inhibitor wogonin and 
observed, 1,25(OH)2D3-induced actin polymerization was totally blocked. On the other 
hand, 1,25(OH)2D3-induced up-regulation of Fgf23 was also abolished by actin 
depolymerising agent cytochalasin B. Hence, 1,25(OH)2D3-stimulated Fgf23 expression is 
at least in part regulated by actin cytoskeleton reorganization. Rac1/PAK1 is a key 
regulatory molecule in the actin signalling pathway in various cell models (212, 219, 220). 
In this study, I used Rac1 and PAK1 specific inhibitor NCS 23766 (50 µM) and IPA3 (10 
µM) respectively, to block actin cytoskeleton and questioned whether it affects gene 
transcription of Fgf23. Indeed, blocking of Rac1 and PAK1 activities lead to the 
suppression of Fgf23 mRNA transcription in UMR 106 cells. This study demonstrated that 
1,25(OH)2D3-induced actin cytoskeleton reorganization regulates Fgf23 gene expression 
by Rac1/PAK1 signaling. 
Early or late actin cytoskeleton reorganization, following modification of actin 
polymerization is initiated by various signals and regulated by distinct signalling pathway 
which has been implicated in the control of gene transcription (221, 222). It has been 
shown that early actin polymerization by various signals may release transcription factor 
such as myocardin-related transcription factor (MRTF) (221, 223, 224), which may in turn 
regulate transcription of various genes (221). Likewise, early actin restructuring, following 
modification of actin polymerization regulates activation of RhoB-gene (225) as well as 
alpha smooth muscle actin (alpha SMA) gene (226) and guanine nucleotide exchanger 
factors (GEF’s) including Net1/Net1A (227). These studies suggested that early actin 
restructuring may regulate transcription of genes encoding specific regulatory effectors 
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(221, 223) and may link early modification of actin cytoskeleton to late cell responses 
controlled by gene activation (221). These results further support this hypothesis. Indeed, 
actin polymerization induced by 1,25(OH)2D3 in UMR 106 osteoblast-like cells seems to 
regulate 1,25(OH)2D3-induced Fgf23 gene expression, as inhibition of actin polymerization 
either by actin microfilament disrupting agent cytochalasin B or by inhibition of specific 
actin signalling molecules (Rac1/PAK1) that govern actin cytoskeleton dynamics, blunted 
1,25(OH)2D3-induced up-regulation of Fgf23 mRNA expression. 
 
Rac1 is a member of small GTPase Rho family. This is a major signalling molecule of actin 
cytoskeleton signalling pathway which act to the downstream of PI3K/FAK1 signaling 
pathway (228). Rac1 may itself stimulate actin polymerization, or it may associate with 
PAK1 that in turn is implicated in actin restructuring (200, 229). These results provide 
strong evidence that Rac1/and PAK1 are mainly involved in both, actin reorganization and 
Fgf23 gene transcription, which support previous studies describing an important role of 
Rac1 in osteoblastic cells (230). In fact, this study cannot exclude the involvement of other 
small Rho-GTPase signaling, may be these signaling involve as well. These findings 
strongly indicate that the Rac1/PAK1-stimulated actin redistribution is required for the 
1,25(OH)2D3-induced production of Fgf23 in UMR 106 osteoblast-like cells. Apart from 
this, as suppression of Fgf23 production by inhibiting NF-κB signaling with wogonin 
resulted in a blockade of actin network reorganization, these findings further support 
previous studies establishing the involvement of NF-κB signaling in actin cytoskeleton 
rearrangements (204, 205, 231). 
 
Rac1/PAK1 signaling may turn out to be a potent regulator of renal phosphate and vitamin 
D metabolism by controlling FGF23 formation through reorganization of actin cytoskeleton. 
Further studies are needed to define its exact role. 
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Fig. 27: Fgf23 gene regulation by actin cytoskeleton reorganization: 1,25(OH)2D3 stimulates Fgf23 
gene transcription in UMR 106 cells. 1,25(OH)2D3-induced Fgf23 expression is inhibited by Rac1 inhibitor 
NSC 23766 and cytochalasin B. Rac1 inhibitor NSC 23766 and PAK inhibitor IPA3 also blocked 
1,25(OH)2D3-induced actin polymerization. Black arrows indicate stimulation and red arrows indicate 
inhibition. 
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6. Conclusion 
 
The present observations reveal that PKB/Akt-resistant GSK3 signaling controls 
sympathetic nervous activity which is an important regulator of FGF23 production and 
phosphate metabolism. Hence, gsk-3KI mice exhibit a high serum FGF23 level, 
phosphaturia, and hypophosphatemia, normalized by β-blocker propranolol.  
 
1,25(OH)2D3-induced Fgf23 gene transcription in UMR 106 cells requires reorganization of 
the actin network, govern by NF-κB and Rac1/PAK1 signaling. These observations reveal 
that actin cytoskeleton reorganization may be implicated in the control of gene 
transcription. 
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